PubMed Health⌕ Search

Biomedical subjects

V Raso

Publications and source records attributed to V Raso.

At least 37 records · Page 2Linked to original sources

Carboxylic ionophores enhance the cytotoxic potency of ligand- and antibody-delivered ricin A chain.

The highly selective cytotoxicity of site-directed ricin A chain conjugates can be potentiated by membrane-active carboxylic ionophores. The combined use of the two agents results in much faster inactivation of ribosomes and subsequent cell death and lysis. The potency of A chain cytotoxins is correspondingly increased by several orders of magnitude and cells that sparsely express the target antigen or receptor can be killed.

Animals↗

A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells.

The toxic A chain of ricin was linked to human transferrin via a disulfide bond and the resulting conjugate was shown to bind to cell membrane transferrin receptors. Surface-localized transferrin A chain (TF-A chain) gained access to the cytoplasm and inactivated ribosomes as witnessed by a rapid curtailment of cellular protein synthesis (t1/2 = 6 h) and subsequent cytolysis. The intact conjugate produced potent cytotoxic effects on human leukemia CEM cells, (ID50 = 3 X 10(-11) M), while a 10,000-fold higher concentration of uncoupled transferrin plus A chain was required for comparable action. TF-A chain cytotoxicity was totally blocked by native transferrin or by antibodies directed against ricin A chain and human transferrin. CEM cells gradually acclimated to grow in the presence of TF-A chain displayed 1000-fold resistance to the conjugate while their sensitivity to whole ricin was undiminished. The level of transferrin receptor expressed by these cells was 1/20 the amount present on the parent line and their capacity to bind human transferrin was below the limits of detectability using fluorescent probes. This receptor-deficient cell line was unresponsive to the low levels of transferrin which stimulated proliferation of control CEM cells, but their growth was supported by greatly elevated concentrations of ligand. Receptor variant CEM cells, together with the specific TF-A chain toxin, will be useful for studying the mechanisms for transmembrane delivery of both Fe3+ and ricin A chain into cells and will aid in understanding the growth regulatory functions of the receptor-ligand interaction.

Cell Line↗

Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.

The toxic subunit of ricin has been conjugated by a disulfide bound to a monoclonal murine antibody (J-5) specific for the common acute lymphoblastic leukemia antigen (CALLA) expressed on human lymphoblastic cells. Both the monoclonal antibody and ricin A chain retained their original biological activity after conjugation. The ricin A chain portion of this conjugate effectively inhibited protein synthesis in a cell-free rabbit reticulocyte lysate system. Its antibody-combining site attached to the membrane of CALLA-bearing cells, whereupon both components of the molecule, antibody and A chain, could be detected using fluorescein-labeled antibody probes directed against either mouse F(ab')2 or ricin A chain. This conjugate proved to be a potent cytotoxin for CALLA-positive Nalm-1 cells growing in vitro and produced 50% inhibition of proliferation at levels of 2 x 10(-10) M. In contrast, CALLA-negative cell lines were unaffected until levels of conjugate approached 10(-6) M. When tested for cytotoxic action on Nalm-1 cells, the composite conjugate molecule was at least 2000 times more effective than J-5 antibody alone, ricin A chain alone, or a noncovalent mixture of these components. Cytotoxicity of the conjugate could be blocked completely by addition of antibodies specific for either mouse immunoglobulin or ricin A chain. Direct comparison of the in vitro cytotoxicity of CALLA-directed univalent Fab versus bivalent F(ab')2 carriers of ricin A chain revealed 70-fold greater efficacy for the latter conjugate. This differential could not be accounted for by differences in A chain activity or binding affinity for the cell membrane but appeared related to the ability of the multivalent agent to induce modulation and internalization of CALLA determinants. No overt toxic effects were noted when the F(ab')2-A chain conjugate was administered i.v. to rabbits at levels as high as 20 mg/kg single injection or 5 mg/kg for 5 days. The unique specificity characteristics and high potency of this cytotoxic conjugate indicate that it has significant therapeutic potential for the treatment of CALLA-bearing human leukemias and lymphomas.

Animals↗

Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells.

Hybrid antibodies possessing one binding site for the toxic lectin ricin and a companion site directed against human immunoglobulin were constructed in vitro. This bifunctional reagent specifically attached to human lymphocyte surface immunoglobulin determinants and, thus situated, could simultaneously capture ricin molecules or its toxic A chain. Attachment of these components to the cell was revealed by specific fluorescein-labeled antibodies. Once concentrated at the target cell membrane, hybrid-bound toxin was subsequently released to function via its normal mechanism of biological action. It gained access to ribosomes, its intracellular target, and curtailed protein synthesis. Toxicity was not augmented for immunoglobulin-negative cells to which hybrid could not bind and free human immunoglobulin G could competitively block the enhanced effects observed for immunoglobulin-bearing cell lines. These results indicate that hybrid antibodies may be utilized to carry active agents within close proximity to the membrane of a specified cell type and thereby selectively enhance their effect.

Antibodies↗

Specific cytotoxicity of a human immunoglobulin-directed Fab'-ricin A chain conjugate.

The toxic A chain of ricin and the Fab' fragment of antibody directed against human immunoglobulin (Ig) have been disulfide linked via their intrinsic sulfhydryl groups. This Fab'-A chain conjugate retained the activities of its component parts. It produced effective inhibition of protein synthesis in a cellfree rabbit reticulocyte lysate system and bound tightly ti Ig determinants on human cells. Attachment of the intact molecule to the cell surface was revealed by using fluorescein-labeled antibodies directed against both its Fab' and A chain halves. The Fab'-A chain conjugate was evaluated for cytotoxicity by using human, surface Ig positive target cells and surface Ig negative control cells. In vitro toxicity was entirely selective since the conjugate produced inhibition of de novo protein synthesis, impedence of growth, as well as death and lysis, only for cells possessing surface Ig determinants. Moreover, the effects on Ig positive cells were abrogated by the addition of free human IgG that competitively blocked the Fab' combining site of this conjugate and prevented cell surface binding. Addition of lactose, which inhibits binding of whole ricin, did not influence the action of the Fab'-A chain conjugate. These results verified that the specific binding site on the antibody half of the molecule could function as a directional carrier that facilitates A chain entry into the cytoplasm. Expression of cytotoxic effects was thereby restricted exclusively to cells bearing the appropriate target site. This new conjugate molecule thus possessed both the absolute specificity of the antibody and the potent lethality of its parent toxin.

Animals↗

Radioimmunoassay for the detection and quantitation of 5-fluorodexoyuridine.

A sensitive radioimmunoassay for 5-fluorodeoxyuridine (FdUrd) and 5-fluoro-2'-deoxyuridine 5'-monophosphate has been developed by using antibody induced in rabbits, [3H]FdUrd, and a separation technique with nitrocellulose filters. Antibody specificity was characterized by using compounds chemically related to FdUrd and comparing their effectiveness for displacing [3H]FdUrd from the antibody-combining site. Drug levels in serum samples from patients receiving FdUrd chemotherapy were easily and rapidly determined, and the serum disappearance of the drug was followed by this method. FdUrd was also detected and quantified in urine samples. According to the antiserum used, as little as 1 to 10 pmol FdUrd were measurable.

Animals↗

In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin.

Neocarzinostatin (NCS) is an acidic protein (molecular weight, 10,700) isolated from Streptomyces carzinostaticus that has antitumor activity both in model rodent systems and in humans. In vitro it inhibits the growth of a human lymphoblastic leukemic cell line (CCRF-CEM) at a very low concentration (the amount of drug that causes a 50% inhibition of growth compared to control cultures as extrapolated from a dose-response curve (ID50), 2.4 X 10(-9) M). We covalently coupled NCS to the N-hydroxysuccinimide ester of agarose and obtained a product that, by a variety of biochemical and immunological criteria, has been demonstrated to be devoid of any free or loosely bound NCS. Agarose-bound NCS, which is unable to enter cells because of its size, retains a significant amount of inhibitory activity (ID50, 6 to 15 X 10(-9) M) and is also capable of inhibiting tritiated deoxythymidine incorporation into CCRF-CEM cells. Since agarose-bound NCS cannot enter mammalian cells, the above findings indicate that NCS is able to exert its toxic effects by binding to or reacting with receptors on the cell membrane.

Animals↗

Radioimmunoassay of neocarzinostatin, an antitumor protein.

Antibodies directed toward the antitumor protein neocarzinostatin (NCS) have been produced in a rabbit by immunization with a highly purified NCS preparation. The antiserum was monospecific and reversed the antibacterial activity of NCS against Sarcina lutea. It cross-reacted with chemically modified derivatives of NCS and mitomalcin but failed to cross-react with macromomycin. A radioimmunoassay procedure has been developed utilizing the antiserum and a biologically active 125I-labeled derivative of NCS. The lower limit of detection by this radioimmunoassay, which involves a double antibody technique for the separation of antibody-bound and free antigen, was 1 X 10(-13) mole. The sensitivity of the assay is such that serum levels of NCS can be determined accurately after administration of the drug to rats at a single dose of 2 mg/kg. Since NCS is now undergoing clinical trial, the radioimmunoassay of the drug will be a valuable tool in clinical pharmacological studies.

Animals↗

The antibody-enzyme analogy. Characterization of antibodies to phosphopyridoxyltyrosine derivatives.

Stable analogs of the crucial Schiff base intermediate of enzymatic and nonenzymatic pyridoxal phosphate catalysis have been used as haptens for induction of specific antibodies. N-(5-phosphopyridoxyl)-3'-amino-L-tyrosine and its conformationally distinct cyclized derivative resemble the Schiff base formed upon mixing tyrosine with pyridoxal phosphate. These compounds were covalently coupled to a protein carrier via the 3'-amino group so as to confer a prescribed orientation, with the coenzyme region farthest removed from the carrier. A third antigen, with the phosphopyridoxyl group alone as the hapten, was prepared by linkage of pyridoxal phosphate directly to free amino groups on the carrier protein. Antibodies elicited for each determinant were purified by means of appropriate affinity columns. Antibody heterogeneity was observed in that different species could be separated from a given serum by sequential elution from the affinity columns with 1 M sodium phosphate buffers of pH 7.6, 5.2, 2.6 and 1.5. In assays of quantitative precipitation, inhibition of precipitation, equilibrium dialysis, and fluorescence quenching, antibodies to the phosphopyridoxyltyrosine haptens showed specificity for the phosphorylated form of the coenzyme and binding activity for both the coenzyme and tyrosine portions of the hapten. Antibodies to the phosphopyridoxyl groups alone did not display a similar reactivity toward the tyrosine portion of the complex haptens. The cyclic and noncyclic conformations of the hapten were serologically distinct, as antibody to each reacted preferentially with the homologous form.

Animals↗

The antibody-enzyme analogy. Comparison of enzymes and antibodies specific for phosphopyridoxyltyrosine.

Reduced Schiff base compounds of pyridoxal-P and tyrosine, which were used to induce specific antibodies described in the preceding article (V. Raso and B. D. Stolar, Biochemistry, 1975), caused active site-directed inhibition of tyrosine transaminase and tyrosine decarboxylase. The antibodies, studied as analogs of enzymes, were able to bind an unsaturated Schiff base catalytic intermediate, as shown by equilibrium dialysis and absorbance difference spectroscopy. Schiff base formation can proceed while the pyridoxal-P and tyrosine are within the antibody combining site, but the rate of this bimolecular condensation within the sites was not greater than the rate in free solution. Antibody did effect a small rate enhancement for the pyridoxal-P-catalyzed transamination of L-tyrosine. These results are discussed in light of current ideas in the mechanisms of enzyme catalysis.

Animals↗

A rapid and specific radioimmunoassay for methotrexate.

A sensitive and precise radioimmunoassay for methotrexate has been developed using antibody induced in rabbits, tritium-labeled methotrexate, and a nitrocellulose membrane separation technique. Antibody specificity was characterized by comparing the effectiveness of various related compounds to displace labeled methotrexate from the antibody-binding site. Assay of serum samples from persons receiving the drug was rapid and easy to perform. In a pharmacokinetic study of methotrexate, corresponding results were obtained when measurements were made by either enzymic assay or by radioimmunoassay. Drug concentrations could also be monitored in the cerebrospinal fluid and urine of patients on high-dose methotrexate therapy followed by citrovorum factor rescue. The system measured a little as 0.1 to 1 pmole of methotrexate, depending upon the antiserum used, and naturally occurring folates did not interfere with these determinations.

Animals↗